Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Change in Account Payables (2016 - 2025)

Historic Change in Account Payables for Arrowhead Pharmaceuticals (ARWR) over the last 16 years, with Q4 2025 value amounting to $15.3 million.

  • Arrowhead Pharmaceuticals' Change in Account Payables rose 39732.81% to $15.3 million in Q4 2025 from the same period last year, while for Dec 2025 it was $18.5 million, marking a year-over-year increase of 8487.39%. This contributed to the annual value of $6.3 million for FY2025, which is 21354.77% up from last year.
  • Arrowhead Pharmaceuticals' Change in Account Payables amounted to $15.3 million in Q4 2025, which was up 39732.81% from -$15.4 million recorded in Q3 2025.
  • Arrowhead Pharmaceuticals' 5-year Change in Account Payables high stood at $28.0 million for Q3 2023, and its period low was -$15.4 million during Q3 2025.
  • Its 5-year average for Change in Account Payables is $2.4 million, with a median of -$54000.0 in 2021.
  • In the last 5 years, Arrowhead Pharmaceuticals' Change in Account Payables soared by 128453.39% in 2022 and then crashed by 50149.61% in 2023.
  • Quarter analysis of 5 years shows Arrowhead Pharmaceuticals' Change in Account Payables stood at -$5.4 million in 2021, then skyrocketed by 61.55% to -$2.1 million in 2022, then tumbled by 501.5% to -$12.5 million in 2023, then skyrocketed by 124.62% to $3.1 million in 2024, then soared by 397.33% to $15.3 million in 2025.
  • Its Change in Account Payables stands at $15.3 million for Q4 2025, versus -$15.4 million for Q3 2025 and $23.4 million for Q2 2025.